ARQT
HOLD / NEUTRALNeutralComposite
57.80
Technical
71.50
Fundamental
48.70
Rank
—
Price
27.10
Hurst
0.52
As of
Aug 6, 2026
Daily
Arcutis Biotherapeutics, Inc.
HealthcareBiotechnologyArcutis Biotherapeutics is a biopharmaceutical company developing and commercializing medications for skin conditions. Its primary offering is ZORYVE, a topical roflumilast formulation available in cream and foam versions for treating plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis affecting the scalp and body. The company also has ARQ-234 in development, a fusion protein designed to activate the CD200 receptor. Based in Westlake Village, California, Arcutis was founded in 2016.
Market cap
$3.3B
P/E (trailing)
120.27
P/E (forward)
19.46
PEG ratio
—
Dividend yield
—
Beta
1.50
52w range
16.57 – 31.77
Return on equity
+15.86%
Profit margin
+6.15%
Revenue growth
+59.30%
Earnings growth
—
Price history
1Y: 26.46 (+49.4%) · range 16.73–31.20
Cycle position
46/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 34 · NOT READY · exit proximity 0
Conviction
30/ 100 · maturity 100%
VScore.405
Buildup.2060
EMA entry setup.2534
Fundamentals.1549
Volume profile
POC
23.83
Price vs POC
+11.0%
Overhead supply
22%
Runway
+0.4%
Value area 23.09–28.36 · 22% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Sep 3, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -10.48% | +0.42% | mature |
| 40d | -9.63% | +0.42% | 25/40d |